ReviewDiscovery medicine2013
Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.
Review in Discovery medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05080270 (Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis.Journal of translational medicine · 2018Trial
- Therapeutic targeting of oligodendrocytes in an agent-based model of multiple sclerosis.PLoS computational biology · 2026Article
- AA147 Alleviates Symptoms in a Mouse Model of Multiple Sclerosis by Reducing Oligodendrocyte Loss.Glia · 2025Article
- Hypoxia in multiple sclerosis.Redox biology · 2025Review
- Article
- Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery.International journal of molecular sciences · 2022Review
- Review
- Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders.Cellular and molecular life sciences : CMLS · 2021Review
- Prolonging the integrated stress response enhances CNS remyelination in an inflammatory environment.eLife · 2021Article
- MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression.Neural regeneration research · 2020Review
- Pre-clinical and Clinical Implications of "Inside-Out" vs. "Outside-In" Paradigms in Multiple Sclerosis Etiopathogenesis.Frontiers in cellular neuroscience · 2020Review
- Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination.Brain structure & function · 2018Article
- Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia.Frontiers in pharmacology · 2018Review
- Corrigendum: Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia.Frontiers in pharmacology · 2018Article
- Attempts to Overcome Remyelination Failure: Toward Opening New Therapeutic Avenues for Multiple Sclerosis.Cellular and molecular neurobiology · 2017Review
- Nimodipine but Not Nifedipine Promotes Expression of Fatty Acid 2-Hydroxylase in a Surgical Stress Model Based on Neuro2a Cells.International journal of molecular sciences · 2017Article
- Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Review
- Dietary cholesterol promotes repair of demyelinated lesions in the adult brain.Nature communications · 2017Article
- Neuroprotection by central nervous system remyelination: Molecular, cellular, and functional considerations.Journal of neuroscience research · 2016Review
- Scutellarin Alleviates Behavioral Deficits in a Mouse Model of Multiple Sclerosis, Possibly Through Protecting Neural Stem Cells.Journal of molecular neuroscience : MN · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) characterized by encephalitogenic leukocyte infiltration and multifocal plaques of demyelination. Patients present with debilitating clinical sequelae including motor, sensory, and cognitive deficits. For the past 30 years, immune modulating treatments have entered the marketplace and continue to improve in limiting the frequency and severity of relapses, but no cure has been found and no drug has successfully stopped chronic progressive disease. Recent work focusing on the oligodendrocyte, the myelin-producing cell, has provided needed insight into the process of demyelination, the spontaneous ability of the CNS to regenerate, and the inevitable failure of remyelination. From this a number of promising molecular targets have been identified to protect oligodendrocytes and promote remyelination. Combining immunomodulatory therapy with strategies to protect oligodendrocytes from further degeneration and enhance remyelination presents a very real means to improve clinical outcome for chronic progressive patients in the near future. Here we lay out a combination therapy approach to treating MS and survey the current literature on promising drug candidates potentially capable of mediating oligodendrocyte protection and enhancing remyelination.
Indexed as
Identifiers
23911232PMC3970909W1588408616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.